Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Anuj Shah, Ruchit Shah, Nehemiah Kebede, Ateesha Mohamed, Marc Botteman, Reg Waldeck & Arif Hussain. (2020) Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy. Journal of Medical Economics 23:4, pages 330-346.
Read now
Read now
Bingcao Wu, Sophia S. Li, Ji Song, Christopher D. Pericone, Ajay S. Behl & Nancy A. Dawson. (2020) Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population. Journal of Medical Economics 23:1, pages 54-63.
Read now
Read now
Elias J. Jabbour, Martin F. Mendiola, Melissa Lingohr-Smith, Jay Lin & Dinara Makenbaeva. (2019) Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. Journal of Medical Economics 22:11, pages 1113-1118.
Read now
Read now
Jinan Liu, Aimee Near, Joseph A. Chiarappa, Keiko Wada, Jenny Tse, Chakkarin Burudpakdee, Ajay Behl, Radhika Ranganath & Emmanuel S. Antonarakis. (2019) Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data. Journal of Medical Economics 22:10, pages 1080-1087.
Read now
Read now
Joerg Mahlich, Akiko Tsubota, Keiichiro Imanaka & Kentaro Enjo. (2018) Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis. Current Medical Research and Opinion 34:10, pages 1855-1860.
Read now
Read now
Joachim Aidt Becker, Kasper Drimer Berg, Martin Andreas Røder, Klaus Brasso & Peter Iversen. (2018) Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review. Scandinavian Journal of Urology 52:1, pages 1-7.
Read now
Read now
A. Armstrong, C. Bui, K. Fitch, T. Goss Sawhney, B. Brown, S. Flanders, M. Balk, J. Deangelis & J. Chambers. (2017) Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. Current Medical Research and Opinion 33:6, pages 1133-1139.
Read now
Read now
Cat N. Bui, Li Wang & Onur Baser. (2014) Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities. Current Medical Research and Opinion 30:11, pages 2355-2364.
Read now
Read now
Przemysław Holko & Paweł Kawalec. (2014) Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Expert Review of Anticancer Therapy 14:1, pages 63-73.
Read now
Read now
DeanG. Cruess, Catherine Benedict, EmilyG. Lattie, Ivan Molton, Dave Kinsinger, Bruce Kava, Murugesan Manoharan, Mark Soloway & FrankJ. Penedo. (2013) Millon Behavioral Medicine Diagnostic (MBMD) Predicts Health-Related Quality of Life (HrQoL) Over Time Among Men Treated for Localized Prostate Cancer. Journal of Personality Assessment 95:1, pages 54-61.
Read now
Read now
Maneesha Mehra, Ying Wu & Ravinder Dhawan. (2012) Healthcare resource use in advanced prostate cancer patients treated with docetaxel. Journal of Medical Economics 15:5, pages 836-843.
Read now
Read now
Nicole M Engel-Nitz, Berhanu Alemayehu, David Parry & Faith Nathan. (2011) Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Management and Research 3, pages 233-245.
Read now
Read now
Articles from other publishers (27)
Marlena Golec, Adam Konka, Martyna Fronczek, Joanna Zembala-John, Martyna Chrapiec, Karolina Wystyrk, Sławomir Kasperczyk, Zenon Brzoza & Rafał Jakub Bułdak. (2022) The Antibody Response to the BNT162b2 mRNA COVID-19 Booster in Healthcare Workers: Association between the IgG Antibody Titers and Anthropometric and Body Composition Parameters. Vaccines 10:10, pages 1638.
Crossref
Crossref
Katrine L. Wallace, Adrienne Landsteiner, Scott H. Bunner, Nicole M. Engel-Nitz & Amy N. Luckenbaugh. (2021) Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes & Control 32:12, pages 1365-1374.
Crossref
Crossref
Luck Hee Sung & Hyeong Dong Yuk. (2020) Role of Cytoreductive Radical Prostatectomy in the Treatment of Metastatic Prostate Cancer. The Korean Journal of Urological Oncology 18:3, pages 161-169.
Crossref
Crossref
Sreevalsa Appukkuttan, Krishna Tangirala, Svetlana Babajanyan, Lonnie Wen, Stacey Simmons & Neal Shore. (2019) A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use. PharmacoEconomics - Open 4:3, pages 439-447.
Crossref
Crossref
Lin Bai, Haishaerjiang Wushouer, Cong Huang, Zhenhuan Luo, Xiaodong Guan & Luwen Shi. (2020) Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017. Frontiers in Pharmacology 11.
Crossref
Crossref
Ronald W. ter Haar, Liselotte M. S. Boevé, Jasper J. Hillenius & George van Andel. (2019) Het klinisch beloop bij gemetastaseerd prostaatcarcinoomClinical course of metastatic prostate cancer. Tijdschrift voor Urologie 9:6-7, pages 131-144.
Crossref
Crossref
Qijie Zhang, Hong Cheng, Yi Wang, Ye Tian, Jiadong Xia, Yichun Wang, Xiang Zhou, Xianghu Meng, Yamin Wang, Min Gu & Ninghong Song. (2019) Different therapeutic regimens in the treatment of metastatic prostate cancer by performing a Bayesian network meta-analysis. International Journal of Surgery 66, pages 28-36.
Crossref
Crossref
Thomas Grochtdreis, Hans-Helmut König, Alexander Dobruschkin, Gunhild von Amsberg & Judith Dams. (2018) Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLOS ONE 13:12, pages e0208063.
Crossref
Crossref
Daniel J. Lee & Neal D. Shore. 2018. Prostate Cancer. Prostate Cancer
121
134
.
Sergio Baldari, Alessandro Sindoni, Laura Evangelista & Emilio Bombardieri. 2018. Clinical Applications of Nuclear Medicine Targeted Therapy. Clinical Applications of Nuclear Medicine Targeted Therapy
365
377
.
Martin Spahn, Alessandro Morlacco, Silvan Boxler, Steven Joniau, Alberto Briganti, Francesco Montorsi, Paolo Gontero, Pia Bader, Detlef Frohneberg, Hein van Poppel & Robert Jeffrey Karnes. (2017) Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients. BJU International 120:5B, pages E52-E58.
Crossref
Crossref
Arie Carneiro, Willy Baccaglini, Felipe P.A. Glina, Paulo P. Kayano, Victor M. Nunes, Oren Smaletz, Wanderley Marques Bernardo, Icaro Thiago de Carvalho & Gustavo Caserta Lemos. (2017) Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis. International braz j urol 43:4, pages 588-599.
Crossref
Crossref
Chiranjeev Sanyal, Armen G. Aprikian, Fabio L. Cury, Simone Chevalier & Alice Dragomir. (2016) Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis. Cancer 122:7, pages 1085-1096.
Crossref
Crossref
Daniela Frasca, Franco Ferracci, Alain Diaz, Maria Romero, Suzanne LechnerBonnie B. Blomberg. (2016) Obesity decreases B cell responses in young and elderly individuals. Obesity 24:3, pages 615-625.
Crossref
Crossref
Cat N. BuiKen O’DayScott FlandersNina OestreicherPeter FrancisLinda Posta, Breanna PopelarHong TangMark Balk. (2016) Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal of Managed Care & Specialty Pharmacy 22:2, pages 163-170.
Crossref
Crossref
Kathryn Martinez, Christopher Friese, Trace Kershaw, Charles Given, Mark Fendrick & Laurel Northouse. (2015) Effect of a Nurse-Led Psychoeducational Intervention on Healthcare Service Utilization Among Adults
With Advanced Cancer. Oncology Nursing Forum 42:4, pages E310-E318.
Crossref
Crossref
Axel Heidenreich, David Pfister & Daniel Porres. (2015) Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control Study. Journal of Urology 193:3, pages 832-838.
Crossref
Crossref
Axel Heidenreich, Daniel Porres & David Pfister. (2015) The Role of Palliative Surgery in Castration-Resistant Prostate Cancer. Oncology Research and Treatment 38:12, pages 670-677.
Crossref
Crossref
Jan Herden, Isabell Heidegger, Pia Paffenholz & Daniel Porres. (2015) Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine. Oncology Research and Treatment 38:12, pages 654-668.
Crossref
Crossref
A. Heidenreich, D. Pfister, B. Brehmer & D. Porres. (2014) Zytoreduktive radikale Prostatektomie beim Prostatakarzinom mit minimaler ossärer MetastasierungCytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases. Der Urologe 54:1, pages 14-21.
Crossref
Crossref
Alice Dragomir, Daniela Dinea, Marie Vanhuyse, Fabio L Cury & Armen G Aprikian. (2014) Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Services Research 14:1.
Crossref
Crossref
Charlotte Piper, Daniel Porres, David Pfister & Axel Heidenreich. (2014) The role of palliative surgery in castration-resistant prostate cancer. Current Opinion in Supportive & Palliative Care 8:3, pages 250-257.
Crossref
Crossref
J. Zeidler, A. Lange, S. Braun, R. Linder, S. Engel, F. Verheyen & J.-M. Graf von der Schulenburg. (2013) Die Berechnung indikationsspezifischer Kosten bei GKV-Routinedatenanalysen am Beispiel von ADHSCalculation of disease-related costs in claims data analyses with the example of attention-deficit hyperactivity disorder. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 56:3, pages 430-438.
Crossref
Crossref
Jennifer B. Christian, Eric J. Olson, Jeffery K. Allen & Kimberly A. Lowe. (2013) HDL-C Response Variability to Niacin ER in US Adults. Cholesterol 2013, pages 1-8.
Crossref
Crossref
C.J. Hirst, C. Cabrera & M. Kirby. (2012) Epidemiology of castration resistant prostate cancer: A longitudinal analysis using a UK primary care database. Cancer Epidemiology 36:6, pages e349-e353.
Crossref
Crossref
M. Kirby, C. Hirst & E. D. Crawford. (2011) Characterising the castration-resistant prostate cancer population: a systematic review. International Journal of Clinical Practice 65:11, pages 1180-1192.
Crossref
Crossref
Dan L. Longo. (2010) New Therapies for Castration-Resistant Prostate Cancer. New England Journal of Medicine 363:5, pages 479-481.
Crossref
Crossref